Eikon Therapeutics vs Verge Genomics (2026)
Both are drug developers built on proprietary biological data, measured very differently. Eikon Therapeutics tracks how individual proteins behave inside living cells with super resolution live cell microscopy and machine learning, and listed on Nasdaq in 2026. Verge Labs, formerly Verge Genomics, works from human brain tissue: 12,000 samples from 6,500 patients and 15 million single cell profiles. Its vBx-1.0 model, released in June 2026, reconstructs a living patient's brain molecular state from blood and genetics. Eikon's data comes from cells in the lab; Verge's comes from patients, and it is specific to neurology.
- Super resolution live cell microscopy that tracks individual proteins inside living cells.
- Machine learning applied to protein behavior observed directly rather than inferred from fixed samples.
- A drug developer led by Roger Perlmutter, listed on Nasdaq in 2026.
- A neurology data asset of brain tissue, multiomic and single cell data from thousands of patients.
- vBx-1.0, which estimates brain molecular state from measurements taken in a living patient.
- A published technical report with measured results against baselines.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Eikon Therapeutics and Verge Genomics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Eikon Therapeutics | Verge Genomics |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2019 | 2015 |
| Headquarters | South San Francisco, CA | South San Francisco, California, United States |
| Website | eikontx.com | vergelabs.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Drug discovery company built around super resolution live cell fluorescence microscopy, applying advanced optics descended from Nobel recognized single molecule imaging work together with machine learning to track how individual proteins behave and move inside living cells, rather than inferring behavior from fixed or lysed samples.
Source: AI Health Index, September 2026
Clinical stage biotechnology company now trading as Verge Labs, applying machine learning to human tissue derived multiomic data in neurology. Over a decade it assembled a proprietary collection it describes as 12,000 brain samples across 6,500 patients with paired proteomic, genomic and clinical data, more than 900 frozen brain tissue samples across the major neurodegenerative diseases, and 15 million single cell profiles.
Source: AI Health Index, September 2026
Questions buyers ask
How do Eikon Therapeutics and Verge Genomics work with the EHR?
For Eikon Therapeutics, the clinical programs reach patients through trial sites rather than through any system the company connects to.
With Verge Genomics, the platform does hold clinical data: the model is trained on patient clinical trajectories alongside brain and blood molecular profiles, and the company offers to stratify a partner's trial population. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How are Eikon Therapeutics and Verge Genomics priced and sold?
In Eikon Therapeutics' case, the capital history is public, including a Nasdaq listing in February 2026, and as a registrant the company now files financial statements and risk factors on a cadence.
For Verge Genomics, the platform is not sold as software: the company works through multi year discovery collaborations, and the shape of the terms is public, combining upfront fees, equity, near term payments, milestones on target validation and development, and downstream royalties, with the partner selecting targets and holding an option to license and advance them. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do Eikon Therapeutics and Verge Genomics cover?
With Eikon Therapeutics, the pipeline page names the areas and the programs: oncology, with a TLR7/8 agonist through Phase 2 and PARP1 programs including a central nervous system penetrant one, plus androgen receptor and VCP programs; and, beyond oncology, immunology and neuroscience, where the company says it invests substantial effort.
In Verge Genomics' case, the data and the model are built for neurodegenerative disease, with the model trained across five diseases and results reported for Parkinson's and Alzheimer's by brain region, and the company's own clinical experience is in ALS. What the platform does within that scope is also named: target discovery, target characterization, biomarker identification and patient stratification. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Eikon Therapeutics and Verge Genomics?
For Eikon Therapeutics, the company says its clinical programs have already shown evidence of activity in solid tumors. The assets that reached patients came from outside the platform: the lead was acquired from a partner and the PARP1 programs were in licensed, while the programs the platform originated remain preclinical.
With Verge Genomics, the company reports 280 or more novel targets surfaced, an 83 percent preclinical validation rate and two AI discovered drugs reaching clinical candidate stage, and states $1.6 billion in partnerships with top 20 pharmaceutical companies. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed on this site in September 2026. Part of Eikon's platform material could not be read for this review, and Verge's move to a partnered foundation model is recent.
Ask both how the cell line or patient derived data behind their models was sourced and governed.